Cambium Bio Limited has released a press release.
Update on licensing Progenza in Japan
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Cambium Bio
- European Medicines Agency grants Progenza ATMP status
- Japanese Patent Office to grant patent for cancer vaccine
- Regeneus Announces Successful Results in Acne Study
- CEO Presentation to 2017 Annual General Meeting
- Sygenus shows longer lasting effect on pain than morphine
Later from Cambium Bio
- US Patent Office to allow key patent for Progenza
- Positive clinical trial results for cancer vaccine
- Regeneus receives R&D tax incentive refund of $2.4m
- Progenza patent to grant in Europe
- Re-Released - Appendix 4C - Quarterly
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio